Sen. Elizabeth Warren, D-Mass., is raising questions about the proposed settlement that Mylan struck with the U.S. Justice Department for overcharging Medicaid for the EpiPen, calling the terms of the deal “shamefully weak.”

Mylan said early this month that it had agreed to pay $465 million to settle claims that it misclassified the EpiPen emergency allergy treatment as a generic instead of a brand-name drug, cheating the government out of millions in rebates.

Ms. Warren said she believes Mylan, whose operations base is in Cecil, defrauded the government by at least $530 million.

“This settlement is shockingly soft on this corporate wrongdoer,” she said in a letter to the Justice Department dated Friday, noting that companies are responsible for ensuring that their drugs are correctly classified.

Advertise with us

“Mylan wrongly classified EpiPen to maximize its Medicaid revenue, and did not change this classification despite being ‘expressly told’ by [Medicaid] that it was wrong,” Ms. Warren wrote.

“The Justice Department rewarded Mylan by imposing a fine that is about $65 million less than the amount Mylan made by defrauding” the government, she said.

“In addition, you permitted Mylan to avoid admitting any admission of wrongdoing, collected no additional penalties under the False Claims Act and blocked other actions against the company that would have required greater accountability.”

Neither the Justice Department nor Mylan responded to emails late Friday seeking comment.

When Mylan announced the settlement, the company said that it would be working with the government to finalize the deal.

Advertise with us

Ms. Warren’s letter asked the Justice Department for a briefing on the settlement by Oct. 28.

“Your department’s limp response to Mylan’s deliberate fraud raises a serious question about exactly how you plan to police other companies if you approve settlements that show that crime does pay,” Ms. Warren said in her letter.

Mylan has drawn intense scrutiny and accusations of price gouging recently for raising the price of the EpiPen more than 500 percent since acquiring the drug in 2007, from around $100 a two-pack to about $600.

Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.